M2 macrophages confer resistance to 5-fluorouracil in colorectal cancer through the activation of CCL22/PI3K/AKT signaling

被引:78
作者
Wei, Chen [1 ,2 ,3 ,4 ]
Yang, Chaogang [1 ,2 ,3 ,4 ]
Wang, Shuyi [1 ,2 ,3 ,4 ]
Shi, Dongdong [1 ,2 ,3 ,4 ]
Zhang, Chunxiao [1 ,2 ,3 ,4 ]
Lin, Xiaobin [1 ,2 ,3 ,4 ]
Xiong, Bin [1 ,2 ,3 ,4 ]
机构
[1] Wuhan Univ, Dept Gastrointestinal Surg, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China
[2] Wuhan Univ, Dept Gastr & Colorectal Surg Oncol, Zhongnan Hosp, Wuhan 430071, Hubei, Peoples R China
[3] Hubei Key Lab Tumor Biol Behav, Wuhan 430071, Hubei, Peoples R China
[4] Hubei Canc Clin Study Ctr, Wuhan 430071, Hubei, Peoples R China
来源
ONCOTARGETS AND THERAPY | 2019年 / 12卷
基金
中国国家自然科学基金;
关键词
M2; macrophages; colorectal cancer; 5-fluorouracil; chemotherapy resistance; CCL22; TUMOR-ASSOCIATED MACROPHAGES; THERAPY; CELLS; PI3K; IMMUNOSUPPRESSION; CHALLENGES; SURVIVAL; PATHWAY;
D O I
10.2147/OTT.S198126
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Background: M2 macrophages are crucial components of tumor microenvironment that frequently associated with the resistance of therapeutic treatments in human cancers, but their role in the chemosensitivity of colorectal cancer (CRC) to 5-fluorouracil (5-FU) is still obscure. Methods: In our study, we clarified the biological functions of M2 macrophages and their mechanism on the chemosensitivity of CRC cells to 5-FU. Then, we analyzed the correlation between CCL22 and CD68(+) and CD163(+) tumor-associated macrophages (TAMs), and further elucidated the prognostic value of CCL22 and CD163(+) M2 macrophages in clinical CRC samples. Results: M2 macrophages decreased the inhibitory effect of 5-FU on CRC cells migration and invasion by secreting CCL22, and declined the apoptosis induced by 5-FU. Treated with a neutralizing anti-CCL22 antibody destroyed these effects. We further illuminated that M2 macrophages regulated 5-FU resistance of CRC cells through epithelial-mesenchymal transition (EMT) program, PI3K/AKT pathway, and caspase-mediated apoptosis. Clinically, CCL22 was found to have elevated expression in CRC tissue samples, and was positively associated with CD163(+) TAMs. Furthermore, the patients with higher CD163(+) M2 macrophages and higher expression of CCL22 in CRC tissues had a lower overall survival (OS) rate compared with lower ones. Conclusion: Our findings indicate that M2 macrophage regulated 5-FU-mediated CRC chemoresistance via the EMT program, PI3K/AKT pathway, and caspase-mediated apoptosis by releasing CCL22.
引用
收藏
页码:3051 / 3063
页数:13
相关论文
共 38 条
  • [1] Type and location of tumor-infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients
    Algars, Annika
    Irjala, Heikki
    Vaittinen, Samuli
    Huhtinen, Heikki
    Sundstrom, Jari
    Salmi, Marko
    Ristamaki, Raija
    Jalkanen, Sirpa
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2012, 131 (04) : 864 - 873
  • [2] [Anonymous], SEMIN ONCOL
  • [3] [Anonymous], NEW ENGL J MED
  • [4] [Anonymous], CELL
  • [5] [Anonymous], 2002, NEW ENGL J MED
  • [6] Global patterns and trends in colorectal cancer incidence and mortality
    Arnold, Melina
    Sierra, Monica S.
    Laversanne, Mathieu
    Soerjomataram, Isabelle
    Jemal, Ahmedin
    Bray, Freddie
    [J]. GUT, 2017, 66 (04) : 683 - 691
  • [7] Gemcitabine resistance in pancreatic ductal adenocarcinoma
    Binenbaum, Yoav
    Na'ara, Shorook
    Gil, Ziv
    [J]. DRUG RESISTANCE UPDATES, 2015, 23 : 55 - 68
  • [8] Apoptosis assays for quantifying the bioactivity of anticancer drug products
    Brunelle, Joslyn K.
    Zhang, Baolin
    [J]. DRUG RESISTANCE UPDATES, 2010, 13 (06) : 172 - 179
  • [9] The role of the CCL22-CCR4 axis in the metastasis of gastric cancer cells into omental milky spots
    Cao, Liang
    Hu, Xiang
    Zhang, Jian
    Huang, Gang
    Zhang, Yi
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12 : 1 - 10
  • [10] Tumor-associated macrophages: The double-edged sword in cancer progression
    Chen, JJW
    Lin, YC
    Yao, PL
    Yuan, A
    Chen, HY
    Shun, CT
    Tsai, MF
    Chen, CH
    Yang, PC
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 953 - 964